CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Rapidly increasing geriatric population and the subsequent increase in the burden of
heart diseases
4.1.2. Growing funding from the public–private organisations for research on cardiac
biomarkers
4.1.3. Growing incidences of cardiovascular diseases and ongoing clinical trials for
identification of novel cardiac biomarkers
4.1.4. Increasing funds by various organisations to stimulate the research and clinical trails in
biomarker testing
4.2. Market Restraints & Challenges
4.2.1. Issues related to regulatory & reimbursement systems and technical problems related to
sample collection and storage
4.2.2. Determining the cardiac marker levels in the laboratory takes substantial time so these
are not useful in myocardial infraction in the acute phase
4.3. Market Opportunities
4.3.1. Point-Of-Care testing with cardiac biomarkers and emerging markets to offer new
growth avenues for market players
CHAPTER 5 GLOBAL CARDIAC MARKER TESTING MARKET – BY TYPE
5.1. Bnp or Nt-Probnp
5.2. Myoglobin
5.3. Hscrp
5.4. Troponin I and T
5.5. CK-MB
5.6. Others
CHAPTER 6 GLOBAL CARDIAC MARKER TESTING MARKET – BY TYPE OF
TESTING
6.1. Point-Of-Care Testing
6.2. Laboratory Testing
CHAPTER 7 GLOBAL CARDIAC MARKER TESTING MARKET – BY PRODUCT
7.1. Instruments
7.1.1. Immunofluorescence
7.1.2. Immunochromatography
7.1.3. Elisa
7.1.4. Chemiluminescence
7.2. Reagents and Kits
CHAPTER 8 GLOBAL CARDIAC MARKER TESTING MARKET – BY DISEASES
8.1. Congestive Heart Failure
8.2. Myocardial Infarction
CHAPTER 9 GLOBAL CARDIAC MARKER TESTING MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10 GLOBAL CARDIAC MARKER TESTING MARKET - COMPANY
PROFILES
10.1. Danaher Corporation
10.2. Biomérieux S.A.
10.3. Alere, Inc.
10.4. Mitsubishi Chemical Holdings Corporation
10.5. The Carlyle Group
10.6. Randox Laboratories Ltd.
10.7. Guangzhou Wondfo Biotech Co., Ltd.
10.8. F. Hoffmann-LA Roche Ltd.
10.9. Abbott Laboratories, Inc.
10.10. Siemens AG
CHAPTER 11 GLOBAL CARDIAC MARKER TESTING MARKET – COMPETITIVE
LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12 MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13 APPENDIX
13.1. List of Tables
13.2. List of Figures
